approved

Приложение 4 на ПЛС от 02.02.2020 г.

Unique identificator:  e32ee62a-20f3-4b49-bfff-c3c71123e114

Current version: 1

Displayed version: 1

Format: CSV

  • Created at: 2020-02-03 12:46:35
  • Created by: georgi_sivchev
  • Updated at: 2020-02-03 12:46:35
records per page
Order by:

ПОЗИТИВЕН ЛЕКАРСТВЕН СПИСЪК

Rituximab EU/1/17/1185/003 Rixathon, Concentrate for solution for infusion, 500 mg/50 ml, -, Pack: 1 vial Sandoz GmbH, Австрия Sandoz GmbH, Австрия 1393.84 278.77 1672.61 4% 10 1403.84 280.77 1684.61 16% 25 1428.84 285.77 1714.61 НСР-17165/01.11.2018 предварително изпълнение 01.11.2018 02.11.2018 Активен 16315
Rituximab EU/1/17/1185/003 Rixathon, Concentrate for solution for infusion, 500 mg/50 ml, -, Pack: 1 vial Sandoz GmbH, Австрия Sandoz GmbH, Австрия 1393.84 278.77 1672.61 4% 10 1403.84 280.77 1684.61 16% 25 1428.84 285.77 1714.61 НСР-17165/01.11.2018 предварително изпълнение 01.11.2018 02.11.2018 Неактивен 16315
Risedronate 5912/ 30.09.2009 Rizida, Film coated tablet, 35, mg, Pack: 4 Тева Фармасютикълс България ЕООД, България TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; IVAX Pharmaceuticals s.r.o., Czech Republic 2.35 0.47 2.82 7% 0.16 2.51 0.5 3.01 20% 0.47 2.98 0.6 3.58 Цената се заличена с Решение НСР-5495/23.01.2015 ; Допуска предварително изпълнение с Решение НСР-5570/29.01.2015 НСР-3441/30.04.2014 22.05.2014 22.05.2014 Заличен 2770
Risedronate 5912/ 30.09.2009 Rizida, Film coated tablet, 35, mg, Pack: 4 Тева Фармасютикълс България ЕООД, България TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; IVAX Pharmaceuticals s.r.o., Czech Republic 2.91 0.58 3.49 7% 0.2 3.11 0.62 3.73 20% 0.58 3.69 0.74 4.43 КЦРР-2313/20.02.2013 07.03.2013 07.03.2013 Неактивен 2770
Risedronate 5912/ 30.09.2009 Rizida, Film coated tablet, 35, mg, Pack: 4 Тева Фармасютикълс България ЕООД, България TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; IVAX Pharmaceuticals s.r.o., Czech Republic 9.92 1.98 11.9 7% 0.69 10.61 2.12 12.73 20% 1.98 12.59 2.52 15.11 КЦРР-680/31.05.2012 14.06.2012 14.06.2012 Неактивен 2770
Risedronate 5912/30.09,2009 Rizida, Film coated tablet, 35, mg, Pack: 4 Тева Фармасютикълс България ЕООД, България TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; Teva Czech Industries s.r.o., Czech Republic; Teva Sante - France 19.54 3.91 23.45 8% 1.56 21.1 4.22 25.32 20% 3.91 25.01 5 30.01 промяна на обстоятелства КЦ-1326/28.01.2010; КЦPP-481/19.04.2012 КЦ-491/04.02.2009 19.02.2009 19.02.2009 Неактивен 2770
Tocilizumab EU/1/08/492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration GmbH, Германия Roche Pharma AG - Germany 1563.84 312.77 1876.61 4% 10 1573.84 314.77 1888.61 16% 25 1598.84 319.77 1918.61 Промяна на обстоятелствата НСР-15981/22.06.2018. НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018; НСР-20223/22.11.2019 Предварително изпълнение 22.11.2019 02.01.2020 Активен 3260
Tocilizumab EU/1/08/492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration GmbH, Германия Roche Pharma AG - Germany 1563.84 312.77 1876.61 4% 10 1573.84 314.77 1888.61 16% 25 1598.84 319.77 1918.61 Промяна на обстоятелствата НСР-15981/22.06.2018. НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018; НСР-20223/22.11.2019 Предварително изпълнение* 22.11.2019 02.12.2019 Неактивен 3260
Tocilizumab EU/1/08/492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration GmbH, Германия Roche Pharma AG - Germany 1600.59 320.12 1920.71 4% 10 1610.59 322.12 1932.71 16% 25 1635.59 327.12 1962.71 Промяна на обстоятелствата НСР-15981/22.06.2018. НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018 13.10.2018 02.11.2018 Неактивен 3260
Tocilizumab EU/1/08/492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration GmbH, Германия Roche Pharma AG - Germany 1600.59 320.12 1920.71 4% 10 1610.59 322.12 1932.71 16% 25 1635.59 327.12 1962.71 Промяна на обстоятелствата НСР-15981/22.06.2018. НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018 13.10.2018 02.11.2018 Неактивен 3260
Tocilizumab EU/1/08/492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration GmbH, Германия Roche Pharma AG - Germany 1600.59 320.12 1920.71 4% 10 1610.59 322.12 1932.71 16% 25 1635.59 327.12 1962.71 Промяна на обстоятелствата НСР-15981/22.06.2018. НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018 13.10.2018 02.11.2018 Неактивен 3260
Tocilizumab EU/1/08/ 492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration GmbH, Германия Roche Pharma AG - Germany 1600.65 320.13 1920.78 4% 10 1610.65 322.13 1932.78 16% 25 1635.65 327.13 1962.78 Промяна на обстоятелствата НСР-15981/22.06.2018. НСР-6424/12.06.2015.; НСР-13341/28.07.2017 12.08.2017 02.08.2018 Неактивен 3260
Tocilizumab EU/1/08/ 492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration Limited, Обединено Кралство Roche Pharma AG - Germany 1600.65 320.13 1920.78 4% 10 1610.65 322.13 1932.78 16% 25 1635.65 327.13 1962.78 НСР-6424/12.06.2015.; НСР-13341/28.07.2017 12.08.2017 02.09.2017 Неактивен 3260
Tocilizumab EU/1/08/ 492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration Limited, Обединено Кралство Roche Pharma AG - Germany 1675.6 335.12 2010.72 4% 10 1685.6 337.12 2022.72 16% 25 1710.6 342.12 2052.72 НСР-6424/12.06.2015. 26.06.2015 26.06.2015 Неактивен 3260
Tocilizumab EU/1/08/492/007 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes Roche Registration Limited, Обединено Кралство Roche Pharma AG - Germany 1795.86 359.17 2155.03 4% 10 1805.86 361.17 2167.03 16% 25 1830.86 366.17 2197.03 НСР-4826/ 13.10.2014 27.10.2014 27.10.2014 Неактивен 3260
Tocilizumab EU/1/08/4 92/009 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens Roche Registration GmbH, Германия Roche Pharma AG, Germany 1563.84 312.77 1876.61 4% 10 1573.84 314.77 1888.61 16% 25 1598.84 319.77 1918.61 НСР-16864/28.09.2018; НСР-20222/22.11.2019 Предварително изпълнение 22.11.2019 02.01.2020 Активен 16292
Tocilizumab EU/1/08/4 92/009 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens Roche Registration GmbH, Германия Roche Pharma AG, Germany 1563.84 312.77 1876.61 4% 10 1573.84 314.77 1888.61 16% 25 1598.84 319.77 1918.61 НСР-16864/28.09.2018; НСР-20222/22.11.2019 Предварително изпълнение* 22.11.2019 02.12.2019 Неактивен 16292
Tocilizumab EU/1/08/4 92/009 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens Roche Registration GmbH, Германия Roche Pharma AG, Germany 1647.81 329.56 1977.37 4% 10 1657.81 331.56 1989.37 16% 25 1682.81 336.56 2019.37 НСР-16864/28.09.2018 13.10.2018 02.11.2018 Неактивен 16292
Tocilizumab EU/1/08/4 92/009 RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens Roche Registration GmbH, Германия Roche Pharma AG, Germany 1647.81 329.56 1977.37 4% 10 1657.81 331.56 1989.37 16% 25 1682.81 336.56 2019.37 НСР-16864/28.09.2018 13.10.2018 02.11.2018 Неактивен 16292
Tocilizumab EU/1/08/492/003 RoActemra, Concentrate for solution for infusion, 20 mg/ml - 10 ml, mg, Pack: 1 Roche Registration GmbH, Германия Roche Pharma AG Germany 514.91 102.98 617.89 4% 10 524.91 104.98 629.89 16% 25 549.91 109.98 659.89 Промяна на обстоятелствата НСР-15987/22.06.2018. НСР-5077/21.11.2014; НСР-13342/28.07.2017 12.08.2017 02.08.2018 Активен 3377
Tocilizumab EU/1/08/492/003 RoActemra, Concentrate for solution for infusion, 20 mg/ml - 10 ml, mg, Pack: 1 Roche Registration GmbH, Германия Roche Pharma AG Germany 514.91 102.98 617.89 4% 10 524.91 104.98 629.89 16% 25 549.91 109.98 659.89 Промяна на обстоятелствата НСР-15987/22.06.2018. НСР-5077/21.11.2014; НСР-13342/28.07.2017 12.08.2017 02.08.2018 Неактивен 3377
Tocilizumab EU/1/08/492/005 RoActemra, Concentrate for solution for infusion, 20 mg/ml - 20 ml, mg, Pack: 1 Roche Registration GmbH, Германия Roche Pharma AG Germany 1029.82 205.96 1235.78 4% 10 1039.82 207.96 1247.78 16% 25 1064.82 212.96 1277.78 Промяна на обстоятелствата НСР-15986/22.06.2018. НСР-5078/21.11.2014; НСР-10019/18.08.2016; НСР-14455/17.11.2017 02.12.2017 02.08.2018 Активен 3378
Tocilizumab EU/1/08/492/005 RoActemra, Concentrate for solution for infusion, 20 mg/ml - 20 ml, mg, Pack: 1 Roche Registration GmbH, Германия Roche Pharma AG Germany 1029.82 205.96 1235.78 4% 10 1039.82 207.96 1247.78 16% 25 1064.82 212.96 1277.78 Промяна на обстоятелствата НСР-15986/22.06.2018. НСР-5078/21.11.2014; НСР-10019/18.08.2016; НСР-14455/17.11.2017 02.12.2017 02.08.2018 Неактивен 3378
Tocilizumab EU/1/08/492/001 RoActemra, Concentrate for solution for infusion, 20 mg/ml - 4 ml, mg, Pack: 1 Roche Registration GmbH, Германия Roche Pharma AG Germany 205.97 41.19 247.16 4% 8.24 214.21 42.84 257.05 16% 25 239.21 47.84 287.05 Промяна на обстоятелствата НСР-15983/22.06.2018. НСР-5076/21.11.2014; НСР-10018/18.08.2016; НСР-14456/17.11.2017 02.12.2017 02.08.2018 Активен 3376
Tocilizumab EU/1/08/492/001 RoActemra, Concentrate for solution for infusion, 20 mg/ml - 4 ml, mg, Pack: 1 Roche Registration GmbH, Германия Roche Pharma AG Germany 205.97 41.19 247.16 4% 8.24 214.21 42.84 257.05 16% 25 239.21 47.84 287.05 Промяна на обстоятелствата НСР-15983/22.06.2018. НСР-5076/21.11.2014; НСР-10018/18.08.2016; НСР-14456/17.11.2017 02.12.2017 02.08.2018 Неактивен 3376
Showing 12851 to 12876 of 17079 entries
Download link in CSV format: Copy
Download link in JSON format: Copy
Download link in XML format: Copy
 

Моля изчакайте